Pharmacy Benefits Management – Page 84

May 8, 2020

May 8, 2020 – The U.S. FDA has approved RetevmoTM (selpercatinib), manufactured by Eli Lilly, to treat certain patients who have lung or thyroid cancer and RET gene alterations.

May 7, 2020

Tabrecta Approved for Lung Cancer

May 7, 2020 – The U.S. FDA has approved TabrectaTM (capmatinib), manufactured by Novartis, to treat adult patients who have metastatic non-small cell lung cancer (NSCLC) and

May 6, 2020

Farxiga Receives New Indication for Heart Failure

May 6, 2020 – The U.S. FDA has approved a new indication for Farxiga® (dapagliflozin) oral tablets, manufactured by AstraZeneca. The drug is now indicated to reduce the risk of

May 4, 2020

Fensolvi Approved for Central Precocious Puberty

May 4, 2020 – The U.S. FDA has approved Fensolvi® (leuprolide acetate), manufactured by Tolmar Pharmaceuticals, to treat pediatric patients two years of age and older who

March 18, 2020

Tecentriq Receives New Lung Cancer Indication

May 18, 2020 – The U.S FDA has approved a new indication for Tecentriq® (atezolizumab), manufactured by Genentech, to provide initial

March 15, 2020

Opdivo and Yervoy Approved for First-Line Treatment of Lung Cancer

May 15, 2020 – The U.S. FDA has approved a new indication for Opdivo® (nivolumab – Bristol Myers Squibb), used in combination with Yervoy® (ipilimumab – Bristol Myers Squibb)

January 23, 2020

Tazverik First Treatment Approved Specifically for Epithelioid Sarcoma

January 23, 2020 – The U.S. FDA has granted accelerated approval to TazverikTM (tazemetostat), manufactured by Epizyme, to treat patients who are at least 16 years old and have metastatic or locally

January 21, 2020

Tepezza First Drug Approved to Treat Thyroid Eye Disease

January 21, 2020 – The U.S. FDA has approved TepezzaTM (teprotumumab-trbw), manufactured by Horizon Therapeutics, to treat thyroid eye disease (TED). It is the first and only FDA-approved therapy for this indication.